By knowing the effect of genes on drug response and metabolism, clinicians can tailor the treatment and drug dose for each individual patient. HSA will also be able to assess the advisability of genetic testing to improve efficacy and safety of treatments, thereby protecting and advancing overall public health.

Associate Professor John Lim said, "This MoU will strengthen the fundamental public health orientation of our work, and supports HSA's aim of advancing thought leadership and innovation in our scientific and regulatory areas of expertise, both locally and globally. By collaborating with SSHSPH in research, teaching and training, we can develop and implement innovative public health solutions relevant to regulatory and analytical science, and transfusion medicine. This fits in well with our established international network of MoU partners and will also help to define key topics for scientific roundtables and research projects under the HSA Academy."